StockData
Electra Therapeutics, Inc. logo

Electra Therapeutics, Inc. (ETRA) shareholders

ETRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$8.35+0.04 (+0.48%)

Close on Nov 17, 2026Market cap $524.94MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
0M
Shares held, 13F filers
Institutional holders
0
0 new, 1 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
36 buys · 0 sales
Net bought $48.70M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Orbimed Advisors LLC
Joint filing with Orbimed Capital Gp Vii LLC (8.20%)
6,885,17011.00%13D (active)Sep 21, 2026
Dr. Beth C. Seidenberg
Joint filing with Westlake BioPartners Fund I, L.P. (5.60%), Westlake BioPartners GP I, LLC (5.60%)
6,347,53910.10%13G (passive)Sep 30, 2026
Redmile Group, LLC
Joint filing with Jeremy C. Green (8.70%), Redmile Biopharma Investments II, L.P. (7.60%)
5,462,8818.70%13G (passive)Sep 21, 2026
LSP 7 Management B.V.
Joint filing with LSP 7 Cooperatief U.A. (6.00%)
3,795,2816.00%13G (passive)Sep 21, 2026

Top institutional holders

13F holdings as of Mar 31, 2026

HolderShares% of ETRAValueChange% of portfolio
Kentucky Retirement Systems23,712–$466.00KNew0.01%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares heldNew / addedReduced / closedShares boughtShares sold
Q2 202600M0 / 00 / 10M0M
Q1 202610M1 / 00 / 00M0M
Q1 202500M0 / 00 / 10M0M
Q4 202410M1 / 00 / 00M0M
Q4 202100M0 / 00 / 10M0M
Q3 202110M1 / 00 / 00M0M
Q1 202100M0 / 00 / 20M0M
Q4 202020M1 / 00 / 4070M204M
Q3 2020410204M43 / 122173 / 4016M25M
Q2 2020407213M57 / 110189 / 6130M33M
Q1 2020412217M64 / 119184 / 11963M59M
Q4 2019473213M83 / 142194 / 6938M34M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
Quehuong (Kathy) DongPresident & CEO, Director455,484Sep 21, 2026
Gary S. KoeChief Technical Officer63,656Sep 21, 2026
Graham ParryChief Scientific Officer85,504Sep 21, 2026
David J. TuckerPrincipal Accounting Officer–Sep 18, 2026
Christopher William ClarkChief Financial Officer–Sep 18, 2026
Kim-Hien DaoChief Medical Officer–Sep 18, 2026
Carl L. GordonDirector, 10% owner2,194,579Nov 10, 2026
Genesis GP LLC OrbiMedDirector, 10% owner–Nov 10, 2026
Capital GP VII LLC OrbiMedDirector, 10% owner5,126,891Nov 10, 2026
Advisors Llc OrbimedDirector, 10% owner2,194,579Nov 10, 2026
Nancy StaglianoDirector255,635Sep 21, 2026
Matthew K. FustDirector–Sep 18, 2026
Westlake BioPartners Fund I, L.P.10% owner–Sep 21, 2026
Westlake BioPartners GP I, LLC10% owner–Sep 21, 2026
Westlake BioPartners GP II, LLC10% owner–Sep 21, 2026
Westlake BioPartners Fund II, L.P.10% owner2,820,403Sep 21, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Carl L. Gordon
Director, 10% owner
Nov 10, 2026Buy+2,000$8.45$16.90K2,194,579
Carl L. Gordon
Director, 10% owner
Nov 10, 2026Buy+20,700$8.45$174.91K5,255,278
Advisors Llc Orbimed
Director, 10% owner
Nov 10, 2026Buy+2,000$8.45$16.90K2,194,579
Advisors Llc Orbimed
Director, 10% owner
Nov 10, 2026Buy+20,700$8.45$174.91K5,255,278
Carl L. Gordon
Director, 10% owner
Nov 9, 2026Buy+16,000$8.24$131.84K2,192,579
Carl L. Gordon
Director, 10% owner
Nov 9, 2026Buy+4,000$8.24$32.96K5,234,578
Advisors Llc Orbimed
Director, 10% owner
Nov 9, 2026Buy+16,000$8.24$131.84K2,192,579
Advisors Llc Orbimed
Director, 10% owner
Nov 9, 2026Buy+4,000$8.24$32.96K5,234,578
Carl L. Gordon
Director, 10% owner
Nov 6, 2026Buy+39,600$7.85$310.86K2,176,579
Carl L. Gordon
Director, 10% owner
Nov 6, 2026Buy+9,816$7.85$77.06K5,230,578
Advisors Llc Orbimed
Director, 10% owner
Nov 6, 2026Buy+39,600$7.85$310.86K2,176,579
Advisors Llc Orbimed
Director, 10% owner
Nov 6, 2026Buy+9,816$7.85$77.06K5,230,578
Carl L. Gordon
Director, 10% owner
Nov 5, 2026Buy+125,200$7.31$915.21K2,136,979
Carl L. Gordon
Director, 10% owner
Nov 5, 2026Buy+30,891$7.31$225.81K5,220,762
Advisors Llc Orbimed
Director, 10% owner
Nov 5, 2026Buy+125,200$7.31$915.21K2,136,979
Advisors Llc Orbimed
Director, 10% owner
Nov 5, 2026Buy+30,891$7.31$225.81K5,220,762
Carl L. Gordon
Director, 10% owner
Nov 4, 2026Buy+20,000$7.07$141.40K2,011,779
Carl L. Gordon
Director, 10% owner
Nov 4, 2026Buy+5,000$7.07$35.35K5,189,871
Carl L. Gordon
Director, 10% owner
Nov 4, 2026Buy+37,100$7.78$288.64K1,991,779
Carl L. Gordon
Director, 10% owner
Nov 4, 2026Buy+9,267$7.78$72.10K5,184,871
Advisors Llc Orbimed
Director, 10% owner
Nov 4, 2026Buy+20,000$7.07$141.40K2,011,779
Advisors Llc Orbimed
Director, 10% owner
Nov 4, 2026Buy+5,000$7.07$35.35K5,189,871
Advisors Llc Orbimed
Director, 10% owner
Nov 4, 2026Buy+37,100$7.78$288.64K1,991,779
Advisors Llc Orbimed
Director, 10% owner
Nov 4, 2026Buy+9,267$7.78$72.10K5,184,871
Carl L. Gordon
Director, 10% owner
Nov 3, 2026Buy+98,600$7.88$776.97K1,954,679
Carl L. Gordon
Director, 10% owner
Nov 3, 2026Buy+24,400$7.88$192.27K5,175,604
Carl L. Gordon
Director, 10% owner
Nov 3, 2026Buy+97,800$7.84$766.75K1,856,079
Carl L. Gordon
Director, 10% owner
Nov 3, 2026Buy+24,313$7.84$190.61K5,151,204
Advisors Llc Orbimed
Director, 10% owner
Nov 3, 2026Buy+98,600$7.88$776.97K1,954,679
Advisors Llc Orbimed
Director, 10% owner
Nov 3, 2026Buy+24,400$7.88$192.27K5,175,604
Advisors Llc Orbimed
Director, 10% owner
Nov 3, 2026Buy+97,800$7.84$766.75K1,856,079
Advisors Llc Orbimed
Director, 10% owner
Nov 3, 2026Buy+24,313$7.84$190.61K5,151,204
Capital GP VII LLC OrbiMed
Director, 10% owner
Sep 21, 2026Buy+333,333$15.00$5.00M5,126,891
Capital GP VII LLC OrbiMed
Director, 10% owner
Sep 21, 2026Conversion+1,087,934––3,090,244
Capital GP VII LLC OrbiMed
Director, 10% owner
Sep 21, 2026Buy+1,000,000$15.00$15.00M1,758,279
Capital GP VII LLC OrbiMed
Director, 10% owner
Sep 21, 2026Conversion+758,279––758,279
Capital GP VII LLC OrbiMed
Director, 10% owner
Sep 21, 2026Conversion+1,703,314––4,793,558
Capital GP VII LLC OrbiMed
Director, 10% owner
Sep 21, 2026Conversion+2,002,310––2,002,310
Carl L. Gordon
Director, 10% owner
Sep 21, 2026Conversion+758,279––758,279
Carl L. Gordon
Director, 10% owner
Sep 21, 2026Conversion+2,002,310––2,002,310
Carl L. Gordon
Director, 10% owner
Sep 21, 2026Conversion+1,087,934––3,090,244
Carl L. Gordon
Director, 10% owner
Sep 21, 2026Buy+1,000,000$15.00$15.00M1,758,279
Carl L. Gordon
Director, 10% owner
Sep 21, 2026Conversion+1,703,314––4,793,558
Carl L. Gordon
Director, 10% owner
Sep 21, 2026Buy+333,333$15.00$5.00M5,126,891
Gary S. Koe
Chief Technical Officer
Sep 21, 2026Conversion+63,656––63,656
Graham Parry
Chief Scientific Officer
Sep 21, 2026Conversion+85,504––85,504
Quehuong (Kathy) Dong
President & CEO, Director
Sep 21, 2026Conversion+455,484––455,484
Nancy Stagliano
Director
Sep 21, 2026Conversion+255,635––255,635

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
1.04%
0M shares short
Days to cover
1.7
At 0M shares a day
Change since last report
+18.2%
From 0M shares
Short volume, 20 days
41.4%
Of volume reported to FINRA

Shares sold short, last 2 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Electra Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 506,125 shares on Sep 21, 2026 over the last 90 days.

See a number that looks wrong?